Recombinant Human Prostasin (PRSS8)

What is the basic structure of human prostasin and how is it processed in vivo?

Human prostasin (PRSS8) is a trypsin-like serine protease that is initially synthesized as a zymogen (preproenzyme). The mature protein consists of residues Ala33-Gly319, with processing that yields a structure where:

• The preproenzyme contains an N-terminal signal sequence, propeptide, and a C-terminal glycosylphosphatidylinositol (GPI) anchor domain

• The proprotein undergoes proteolytic cleavage to produce a light chain and a heavy chain connected by a disulfide bond

• The active form results when the propeptide is cleaved, most commonly by enterokinase in experimental settings

In recombinant expression systems, researchers typically replace the native signal sequence and propeptide with insect cell signal sequences (like melittin, GP64, or GP67) to generate the native N-terminus of the mature protein .

Which regions of the human body express prostasin, and at what relative levels?

Prostasin demonstrates a tissue-specific expression pattern:

• Highest expression occurs in the prostate epithelium

• Moderate to lower expression is found in the lung, kidney, liver, salivary gland, and pancreas

• The protein is detected in bodily fluids including seminal fluid, urine, and serum

Western blot analysis of human prostate tissue shows prostasin appearing as a specific band at approximately 40 kDa under non-reducing conditions . Immunohistochemistry confirms specific cytoplasmic localization in prostate tissue sections .

What are the functional differences between membrane-bound and soluble forms of prostasin?

Prostasin exists in two main forms with distinct properties:

The C-terminal membrane-spanning domain can be proteolytically processed to generate the secreted form, which has been purified from seminal fluid . For recombinant production, researchers often replace the GPI anchor domain with a His-tag to facilitate purification and create a soluble form .

What are the optimal expression systems for producing active recombinant human prostasin?

Multiple expression systems have been utilized for prostasin production, each with specific advantages and limitations:

For crystallography and structural studies, baculovirus expression followed by appropriate purification has proven successful . For bacterial expression, researchers have developed effective refolding protocols with glutathione redox systems . Key strategies include:

• Replacing the native signal sequence with an insect cell signal sequence for proper processing

• Mutation of non-essential cysteines (C154S and C203A) to improve stability

• Removal of N-linked glycosylation sites for crystallization studies

How should recombinant prostasin be activated, and what assays can verify its enzymatic activity?

Activation protocol for recombinant prostasin zymogen:

• Convert zymogen to active form using enterokinase (2 units/ml or 7.5 units/mg prostasin)

• Include 0.5 mM reduced glutathione during cleavage reaction

• Maintain reaction at 4°C for 48 hours

• Add 1 mM oxidized glutathione and incubate overnight at 4°C

• Purify using Ni(II) affinity and anion exchange chromatography

The standard enzymatic activity assay procedure:

• Prepare assay buffer: 50 mM Tris, 0.05% (w/v) Brij 35, pH 9.5

• Dilute recombinant prostasin to 20 μg/mL in assay buffer

• Dilute substrate (BOC-Gln-Ala-Arg-AMC) to 200 μM in assay buffer

• Load 50 μL of diluted prostasin into a well of a black microtiter plate

• Add 50 μL of diluted substrate to start the reaction

• Include a substrate blank control

• Read fluorescence at excitation/emission wavelengths of 380/460 nm

• Calculate specific activity using the formula:
  Specific Activity (pmol/min/μg) = [Adjusted Vmax (RFU/min) × Conversion Factor (pmol/RFU)] ÷ amount of enzyme (μg)

What are the critical considerations when using carrier-free versus BSA-containing prostasin formulations?

The choice between carrier-free and BSA-containing recombinant prostasin depends on experimental objectives:

For carrier-free formulations, proper storage is critical:

• Store immediately upon receipt at recommended temperature

• Use a manual defrost freezer

• Avoid repeated freeze-thaw cycles

The carrier-free formulation is typically supplied as a 0.2 μm filtered solution in Tris, NaCl, and CaCl₂ .

How does prostasin regulate epithelial sodium channels (ENaC) and what experimental approaches best demonstrate this interaction?

Prostasin plays a critical role in ENaC regulation through proteolytic processing of channel subunits:

• Prostasin cleaves the γ-subunit of ENaC, removing an inhibitory peptide and thus activating the channel

• This activation increases sodium reabsorption in the distal nephron

Experimental approaches to study this interaction include:

• Oocyte expression systems: Co-expression of prostasin and ENaC in Xenopus oocytes to measure channel activity

• Cell-based assays: Using mouse cortical collecting duct cell lines to assess ENaC function

• In vivo models: Comparing ENaC activity in wild-type versus prostasin mutant mice

Interestingly, studies with prostasin mutants have yielded surprising insights:

• Mice expressing enzymatically inactive endogenous prostasin (Prss8 Cat−/Cat−) display normal tissue development and homeostasis, unlike prostasin null mice (Prss8 −/−)

• This suggests prostasin may have both catalytic and non-catalytic functions, potentially serving as an allosteric regulator of other membrane-anchored proteases

What role does prostasin play in metabolic disorders and what are the key experimental findings?

Recent research has revealed important connections between prostasin and metabolic disorders:

• Hepatic insulin sensitivity:

  • Prostasin cleaves toll-like receptor 4 (TLR4) and regulates hepatic insulin sensitivity

  • In liver-specific PRSS8 transgenic (LTg) mice, high-fat-diet feeding resulted in improved glucose tolerance and reduced hepatic steatosis independent of body weight

  • These effects were associated with amplified extracellular signal-regulated kinase phosphorylation and matrix metalloproteinase 14 activation

• Type 2 diabetes associations:

  • Serum PRSS8 levels are reduced in type 2 diabetes mellitus patients compared to healthy controls

  • Lower levels occur in T2DM patients with increased maximum carotid artery intima media thickness (>1.1 mm)

  • Serum PRSS8 levels correlate with an index of insulin secretory function (HOMA-β) in nondiabetic individuals

• Molecular mechanisms:

  • In liver-specific prostasin transgenic mice fed a high-fat diet, gene expression analysis revealed:

    • Increased expression of Glut4, Acox1, and Ppara in white adipose tissue

    • Decreased expression of inflammatory markers (Tnfa, Ccl2, Ccr2, and Emr1)

These findings suggest that prostasin could represent a potential therapeutic target for obesity-triggered insulin resistance and dyslipidemia.

How can researchers distinguish between catalytic and non-catalytic functions of prostasin?

Distinguishing between catalytic and non-catalytic functions requires sophisticated experimental approaches:

• Mutant prostasin models:

  • Catalytically inactive prostasin (Prss8-S238A): Contains a mutation in the catalytic triad

  • Zymogen-locked prostasin (Prss8-R44Q): Cannot undergo proteolytic activation

  • Complete knockout (Prss8−/−): Absence of the protein

• Key experimental findings:

  • Prss8−/− mice die within 48 hours after birth

  • Prss8 Cat−/Cat− mice (catalytically inactive) develop normally with similar survival rates to wild-type

  • Prss8 Cat−/− mice (heterozygous) show 73% survival through the preweaning period

• Biochemical verification:
  Western blot analysis shows:

  • Wild-type and S238A prostasin appear as ~39 kDa bands (processed form)

  • R44Q prostasin appears as ~41 kDa band (zymogen form)

  • After deglycosylation, bands appear at ~26 kDa and ~28 kDa respectively

This evidence strongly suggests that some essential functions of prostasin are independent of its catalytic activity, with prostasin potentially acting as an allosteric regulator of other proteases.

What controls should be included when studying prostasin in functional assays?

For robust experimental design, include these essential controls:

• Enzymatic activity assays:

  • Substrate blank (buffer + substrate without enzyme)

  • Calibration standard using 7-amino, 4-Methyl Coumarin (AMC)

  • Known inhibitors (aprotinin, nafamostat mesylate) as negative controls

  • Heat-inactivated prostasin to distinguish enzymatic from non-enzymatic effects

• Recombinant protein validation:

  • SDS-PAGE under reducing and non-reducing conditions

  • Mass spectrometry to confirm protein identity and processing

  • Western blot with anti-prostasin antibodies (typically showing bands at ~40 kDa)

• Cell-based and in vivo studies:

  • Wild-type prostasin

  • Catalytically inactive mutant (S238A)

  • Zymogen-locked mutant (R44Q)

  • Complete knockout

  • Vector-only/vehicle controls for transfection/treatment studies

How should researchers interpret contradictory findings about prostasin's role in different physiological contexts?

Several apparent contradictions exist in prostasin research that require careful interpretation:

• Blood pressure regulation paradox:

  • Prostasin activates ENaC, which should increase blood pressure

  • Yet liver-specific prostasin knockout mice show insulin resistance but no clear blood pressure phenotype

  Interpretation approach: Consider tissue-specific effects and compensatory mechanisms. Analyze the entire renin-angiotensin-aldosterone system rather than isolated components.

• Catalytic vs. non-catalytic function contradiction:

  • Catalytic activity is essential for ENaC activation in vitro

  • Catalytically inactive mice develop normally, unlike complete knockout mice

  Interpretation approach: Examine protein-protein interactions and potential scaffolding functions. Consider that catalytic activity may be compensated by other proteases in vivo but not in simpler in vitro systems.

• Metabolic effects discrepancy:

  • Serum prostasin is lower in T2DM patients (suggesting protective role)

  • But some studies suggest prostasin can impair insulin signaling

  Interpretation approach: Distinguish between correlation and causation. Consider measuring both local tissue levels and circulating levels. Account for potential feedback mechanisms.

What are common troubleshooting issues when working with recombinant prostasin and how can they be addressed?

For recombinant prostasin expressed in bacterial systems, the refolding process is critical:

• Testing different buffer additives shows varying efficiency:

  • No additives: Poor recovery

  • 2M urea: Improved recovery

  • 0.4M L-arginine: Highest recovery of soluble protein

What methodological approaches allow researchers to study prostasin-protein interactions?

To investigate prostasin interactions with other proteins, researchers can employ the following approaches:

• Biochemical approaches:

  • Co-immunoprecipitation using anti-prostasin antibodies (such as clone 530622)

  • Pull-down assays using His-tagged recombinant prostasin

  • Surface plasmon resonance to study binding kinetics

  • Enzyme activity modulation assays with potential binding partners

• Cell-based approaches:

  • Co-localization studies using fluorescently tagged proteins

  • Proximity ligation assays to verify protein-protein interactions

  • FRET/BRET to measure direct interactions in living cells

  • Membrane fractionation to identify compartment-specific interactions

• Substrate identification:

  • Proteomics approaches with active vs. inactive prostasin

  • Candidate substrate screening using fluorogenic peptides

  • In-gel zymography for detection of proteolytic activity

  • Known substrates include:

    • Epithelial sodium channel (ENaC) γ-subunit

    • Toll-like receptor 4 (TLR4)

    • Potential activation of matrix metalloproteinase 14

These methodologies provide complementary information about prostasin's interaction partners and help define its functional roles in different physiological contexts.